Table 1.

Clinical trials testing iPSC-derived NK and T cells

Trial #	Phase	Product	Disease settings	Stage
NCT03841110	1	Nontransduced iPSC-derived NK cells (FT500) with checkpoint blockade	Advanced solid tumors	Active, not recruiting
NCT04363346	1	FT516 (hnCD16) iPSC-derived NK cells	COVID-19	Completed
NCT04023071	1	FT516 (hnCD16) iPSC-derived NK cells with obinutuzumab	AML, B-cell lymphoma	Recruiting
NCT04630769	1	FT516 (hnCD16) iPSC-derived NK cells with enoblituzumab and IL-2	Ovarian cancer	Completed
NCT04551885	1	FT516 (hnCD16) iPSC-derived NK cells with avelumab	Advanced solid tumors	Active, not recruiting
NCT04714372	1	FT538 (hnCD16/CD38KO/IL-15RF) iPSC-derived NK cells with daratumumab	AML	Recruiting
NCT05069935	1	FT538 (hnCD16/CD38KO/IL-15RF) iPSC-derived NK cells with monoclonal antibodies	Advanced solid tumors	Recruiting
NCT04614636	1	FT538 (hnCD16/CD38KO/IL-15RF) iPSC-derived NK cells with daratumumab or elotuzumab	AML, multiple myeloma	Recruiting
NCT04555811	1	FT596 (hnCD16/anti-CD19 CAR/IL-15RF) iPSC-derived NK cells with rituximab	NHL, diffuse large B-cell lymphoma, high-grade B-cell lymphoma	Recruiting
NCT04245722	1	FT596 (hnCD16/anti-CD19 CAR/IL-15RF) iPSC-derived NK cells with rituximab or obinutuzumab	B-cell lymphoma, CLL	Recruiting
NCT05395052	1	FT536 (hnCD16/CD38KO/anti-MICA/B CAR/IL-15RF) iPSC-derived NK cells with monoclonal antibodies	Advanced solid tumors	Recruiting
NCT05182073	1	FT576 (IL-15RF/CD38KO/anti-BCMA CAR) iPSC-derived NK cells with daratumumab	Multiple myeloma	Recruiting
NCT05336409	1	CNTY-101 (sIL-15/EGFRt/anti-CD19 CAR) iPSC-derived T cells with IL-2	CD19+ B-cell malignancies NHL	Not yet recruiting
NCT04629729	1	FT819 (CD8αβ anti-CD19 CAR) iPSC-derived T cells with IL-2	Lymphoma, CLL, precursor B-cell ALL	Recruiting

ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma.